Cash Expected to Fund Operations into Q2 2018
Prescription Drug User Fee Act (PDUFA) Goal Date for Twirla® is December 26, 2017
PRINCETON, N.J., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, today reported financial results for the three and nine months ended September 30, 2017, and provided a corporate update for the third quarter 2017.
Third quarter 2017 and other recent corporate developments include:
"This is an exciting time for the company as we continue preparing for the potential approval and commercialization of Twirla, our novel once-weekly contraceptive patch. If approved, Twirla would be the first low-dose non-daily alternative to an oral combined hormonal contraceptive introduced in over 15 years and represents a significant market opportunity," stated Al Altomari, Chairman and Chief Executive Officer of Agile. "We look forward to the potential growth opportunity ahead as we continue to execute on our strategic plans in preparation for our PDUFA goal date of December 26, 2017."
Third Quarter Financial Results
About Agile Therapeutics, Inc.
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com. The company may occasionally disseminate material, nonpublic information on the company website.
Certain information contained in this press release includes "forward-looking statements" related to the Company's clinical trials, regulatory submissions, projected cash position and potential market opportunity for its product candidates. We may, in some cases, use terms such as "predicts," "believes," "potential," "continue," "anticipates," "estimates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions and uncertainties. Any or all of the forward-looking statements may turn out to be wrong, or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Our statements about the results and conduct of our clinical trial could be affected by the potential that there are changes in the data or interpretation of the data by the FDA (for example, the FDA may include additional pregnancies in its calculation of the Pearl Index, which would increase the Pearl Index), whether the results will be deemed satisfactory by the FDA (for example, we describe the results of the SECURE trial as positive, the FDA may disagree with that characterization), and whether additional studies will be required or other issues will arise that will negatively impact acceptance, review, and approval of Twirla by the FDA; our statements about our projected cash position could be affected by market factors, the inherent risks in our business, our ability to execute the Company's operational and budget plans, the FDA does not approve Twirla, the FDA's timeline for review is not completed by the target PDUFA goal date, our ability to timely complete the qualification and validation of our commercial manufacturing process, the fact that our existing cash and cash equivalents will not be sufficient to fund our current and planned operations through the next 12 months, which raises substantial doubt about our ability to continue as a going concern, and which, in turn, may create negative reactions to the price of our common stock making it more difficult to obtain financing in the future, and unforeseen events in our clinical and manufacturing development plans; and our statements about the potential commercial opportunity could be affected by the potential that our product does not receive regulatory approval, does not receive reimbursement by third party payors, or a commercial market for the product does not develop because of any of the risks inherent in the commercialization of contraceptive products. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. All forward-looking statements are subject to risks detailed in our filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Source: Agile Therapeutics
Contact: Mary Coleman -- 609-356-1921
|Agile Therapeutics, Inc.|
Condensed Balance Sheets
|Cash and cash equivalents||$||43,806||$||48,750|
|Total current assets||44,967||51,518|
|Property and equipment, net||13,426||12,330|
|Liabilities and stockholders' equity|
|Accounts payable and accrued expenses||$||4,680||$||5,694|
|Loan payable, current portion||6,190||5,104|
|Total current liabilities||10,960||10,970|
|Loan payable, long‑term||5,887||10,607|
|Additional paid‑in capital||257,093||235,754|
|Total stockholders' equity||41,564||42,289|
|Total liabilities and stockholders' equity||$||58,411||$||63,866|
|Agile Therapeutics, Inc.|
Condensed Statements of Operations
(in thousands, except share and per share amounts)
|Three Months Ended |
|Nine Months Ended|
|Research and development||$||3,175||$||4,911||$||11,694||$||15,415|
|General and administrative||3,526||2,180||9,130||6,497|
|Total operating expenses||6,701||7,091||20,824||21,912|
|Loss from operations||(6,701||)||(7,091||)||(20,824||)||(21,912||)|
|Other income (expense)|
|Change in fair value of warrants||(20||)||38||82||168|
|Loss before benefit from income taxes||(7,102||)||(7,804||)||(22,064||)||(23,540||)|
|Benefit from income taxes||—||—||—||—|
|Net loss per share — basic and diluted||$||(0.22||)||$||(0.27||)||$||(0.74||)||$||(0.84||)|
|Weighted‑average shares outstanding — basic and diluted||31,937,628||28,754,458||29,847,972||28,110,587|